EU Considers mCombriax for 2026-2027 Season Amid Regulatory Divide

EMA's CHMP recommended approval for Moderna's mCombriax, a combined COVID-19 and flu vaccine for people aged 50+.
8,000-participant study showed mCombriax produced stronger antibody responses than separate shots, targeting SARS-CoV-2, influenza A H1N1, H3N2, and influenza B Victoria.
European Commission will review CHMP recommendation, likely using mCombriax in 2026-2027 season.
Moderna withdrew U.S. application, stock fell nearly 90% from 2021 highs.

Healthcare | Vaccines | Regulatory Affairs

United States | European Union

European Commission | Moderna | EMA

2 days ago